165 related articles for article (PubMed ID: 27236298)
21. Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme.
Nomura M; Ito K; Miyakubo M; Sekine Y; Tamura Y; Shimizu N; Aoki S; Suzuki K
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):202-9. PubMed ID: 22143446
[TBL] [Abstract][Full Text] [Related]
22. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of a nomogram including lymphocyte-to-monocyte ratio for initial prostate biopsy: a double-center retrospective study.
Zhou ZH; Liu F; Wang WJ; Liu X; Sun LJ; Zhu Y; Ye DW; Zhang GM
Asian J Androl; 2021; 23(1):41-46. PubMed ID: 32503957
[TBL] [Abstract][Full Text] [Related]
24. The roles of prostate-specific antigen (PSA) density, prostate volume, and their zone-adjusted derivatives in predicting prostate cancer in patients with PSA less than 20.0 ng/mL.
Shen P; Zhao J; Sun G; Chen N; Zhang X; Gui H; Yang Y; Liu J; Shu K; Wang Z; Zeng H
Andrology; 2017 May; 5(3):548-555. PubMed ID: 28409907
[TBL] [Abstract][Full Text] [Related]
25. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.
Briganti A; Larcher A; Abdollah F; Capitanio U; Gallina A; Suardi N; Bianchi M; Sun M; Freschi M; Salonia A; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2012 Mar; 61(3):480-7. PubMed ID: 22078338
[TBL] [Abstract][Full Text] [Related]
26. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
[TBL] [Abstract][Full Text] [Related]
27. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
28. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume.
Remzi M; Fong YK; Dobrovits M; Anagnostou T; Seitz C; Waldert M; Harik M; Marihart S; Marberger M; Djavan B
J Urol; 2005 Oct; 174(4 Pt 1):1256-60; discussion 1260-1; author reply 1261. PubMed ID: 16145388
[TBL] [Abstract][Full Text] [Related]
29. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy.
Lughezzani G; Lazzeri M; Larcher A; Lista G; Scattoni V; Cestari A; Buffi NM; Bini V; Guazzoni G
J Urol; 2012 Oct; 188(4):1144-50. PubMed ID: 22901589
[TBL] [Abstract][Full Text] [Related]
30. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.
Kawakami S; Koga F; Fujii Y; Saito K; Yamamoto S; Tatokoro M; Yonese J; Kageyama Y; Fukui I; Kihara K
Int J Urol; 2008 Dec; 15(12):1055-60. PubMed ID: 19054174
[TBL] [Abstract][Full Text] [Related]
31. Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.
Rubio-Briones J; Borque A; Esteban LM; Casanova J; Fernandez-Serra A; Rubio L; Casanova-Salas I; Sanz G; Domínguez-Escrig J; Collado A; Gómez-Ferrer A; Iborra I; Ramírez-Backhaus M; Martínez F; Calatrava A; Lopez-Guerrero JA
BMC Cancer; 2015 Sep; 15():633. PubMed ID: 26362197
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis of isolated high-grade prostatic intra-epithelial neoplasia: proposal of a nomogram for the prediction of cancer detection at saturation re-biopsy.
Roscigno M; Scattoni V; Freschi M; Abdollah F; Maccagnano C; Galosi A; Lacetera V; Montironi R; Muzzonigro G; Deho F; Deiana G; Belussi D; Chinaglia D; Montorsi F; Da Pozzo LF
BJU Int; 2012 May; 109(9):1329-34. PubMed ID: 21895935
[TBL] [Abstract][Full Text] [Related]
33. Development, validation and comparison of two nomograms predicting prostate cancer at initial 12-core biopsy.
Nowroozi MR; Amini S; Kasaeian A; Zavarehei MJ; Eshraghian MR; Ayati M
Asia Pac J Clin Oncol; 2016 Jun; 12(2):e289-97. PubMed ID: 24684767
[TBL] [Abstract][Full Text] [Related]
34. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.
Kawakami S; Numao N; Okubo Y; Koga F; Yamamoto S; Saito K; Fujii Y; Yonese J; Masuda H; Kihara K; Fukui I
Eur Urol; 2008 Sep; 54(3):601-11. PubMed ID: 18207312
[TBL] [Abstract][Full Text] [Related]
35. The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram.
Tanaka N; Shimada K; Nakagawa Y; Hirao S; Watanabe S; Miyake M; Anai S; Hirayama A; Konishi N; Fujimoto K
BMC Res Notes; 2015 Nov; 8():689. PubMed ID: 26581414
[TBL] [Abstract][Full Text] [Related]
36. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
[TBL] [Abstract][Full Text] [Related]
37. A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer.
Tang P; Chen H; Uhlman M; Lin YR; Deng XR; Wang B; Yang WJ; Xie KJ
Asian J Androl; 2013 Jan; 15(1):129-33. PubMed ID: 23291910
[TBL] [Abstract][Full Text] [Related]
38. Assessing individual risk for prostate cancer.
Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Appu S; Loblaw DA; Sugar L; Narod SA; Kattan MW
J Clin Oncol; 2007 Aug; 25(24):3582-8. PubMed ID: 17704405
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
Chun FK; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Stillebroer AB; van Gils MP; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Haese A
Eur Urol; 2009 Oct; 56(4):659-67. PubMed ID: 19304372
[TBL] [Abstract][Full Text] [Related]
40. Factors predicting prostatic biopsy Gleason sum under grading.
Stackhouse DA; Sun L; Schroeck FR; Jayachandran J; Caire AA; Acholo CO; Robertson CN; Albala DM; Polascik TJ; Donatucci CF; Maloney KE; Moul JW
J Urol; 2009 Jul; 182(1):118-22; discussion 123-4. PubMed ID: 19447436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
